Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology. 1995;9(11):47–60.
Osoba D. Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol. 2011;3(2):57–71.
Haraldstad K, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019;28(10):2641–50.
Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74(235):65132–3.
National Cancer Institute. Cancer statistics. National Cancer Institute; 2020. https://www.cancer.gov/about-cancer/understanding/statistics. Accessed 14 Dec 2020.
Miller KD, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57(5):278–300.
Cella D, Stone AA. Health-related quality of life measurement in oncology: advances and opportunities. Am Psychol. 2015;70(2):175.
Cella D, et al. Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial. J Clin Oncol. 2018;36(8):757.
Cella D, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019;20(2):297–310.
Bouchard LC, Aaronson N, Gondek K, Cella D. Cancer symptom response as an oncology clinical trial end point. Expert Rev Qual Life Cancer Care. 2018;3(2–3):35–46.
Basch E, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007;25(34):5374–80.
Basch E, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. JNCI: J Natl Cancer Inst. 2009;101(23):1624–32.
Cella D, Wagner L. Re-personalizing precision medicine: is there a role for patient-reported outcomes? J Commun Supp Oncol. 2015;13:274–7.
Atkinson TM, et al. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol. 2017;143(4):735–43.
Jim H, McLeod HL. American Society of Clinical Oncology value framework: importance of accurate toxicity data. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(10):1133–4.
Garcia SF, et al. Implementing electronic health record–integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center. Cancer. 2019;125(22):4059–68.
Sisodia RC, et al. Factors associated with increased collection of patient-reported outcomes within a large health care system. JAMA Netw Open. 2020;3(4):e202764.
Gnanasakthy A, Barrett A, Evans E, D’Alessio D, Romano CD. A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012–2016). Value Health. 2019;22(2):203–9.
Cella D, et al. Patient-reported outcomes in performance measurement. Research Triangle Park: RTI Press; 2015.
Cella DF. Quality of life: the concept. J Palliat Care. 1992;8(3):8–13.
Cella DF, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.
Cella DF. Quality of life: concepts and definition. J Pain Symptom Manag. 1994;9(3):186–92.
Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Investig. 1993;11(3):327–36.
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy—Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12(3):199–220.
Brady MJ, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.
Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8(3):181–95.
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–8.
Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Sage Publications; 2004.
Glaser B, Strauss A. The discovery of grounded theory. In: Strategies for qualitative research. Mill Valley: The Sociology Press; 1967.
Acquadro C, et al. Emerging good practices for translatability assessment (TA) of patient-reported outcome (PRO) measures. J Patient Rep Outcomes. 2018;2(1):1–11.
Bonomi A, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996;5(3):309–20.
Wild D, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8(2):94–104.
Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005;28(2):212–32.
Beck CT, Bernal H, Froman RD. Methods to document semantic equivalence of a translated scale. Res Nurs Health. 2003;26(1):64–73.
Cella D, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010;63(11):1179–94.
DeWalt DA, Rothrock N, Yount S, Stone AA. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007;45(5 Suppl 1):S12.
Khadka J, Gothwal VK, McAlinden C, Lamoureux EL, Pesudovs K. The importance of rating scales in measuring patient-reported outcomes. Health Qual Life Outcomes. 2012;10(1):1–13.
Bowling A. Research methods in health: investigating health and health services. Open University Press; 1997.
Condon DM, et al. Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall. Qual Life Res. 2020;29(3):745–53.
Lozano LM, García-Cueto E, Muñiz J. Effect of the number of response categories on the reliability and validity of rating scales. Methodology. 2008;4(2):73–9.
Tsao M, Barnes E, Danjoux C, Sahgal A, Soliman H, Chow E. The Functional Assessment of Cancer Therapy-Brain (FACT-Br) for assessing quality of life in patients with brain metastases: a comparison of recall periods. J Pain Manag. 2013;6(3):223.
Flynn KE, et al. Can 7 or 30-day recall questions capture self-reported lower urinary tract symptoms accurately? J Urol. 2019;202(4):770–8.
Lai J-S, Cook K, Stone A, Beaumont J, Cella D. Classical test theory and item response theory/Rasch model to assess differences between patient-reported fatigue using 7-day and 4-week recall periods. J Clin Epidemiol. 2009;62(9):991–7.
Hahn EA, et al. The talking touchscreen: a new approach to outcomes assessment in low literacy. Psycho-Oncology. 2004;13(2):86–95.
Lee MK, et al. Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Patient Rep Outcomes. 2020;4(1):1–11.
Cella D, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012;78(23):1860–7.
Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review. Value Health. 2008;11(2):322–33.
Ring AE, Cheong KA, Watkins CL, Meddis D, Cella D, Harper PG. A randomized study of electronic diary versus paper and pencil collection of patient-reported outcomes in patients with non-small cell lung cancer. Patient. 2008;1(2):105–13.
Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE Jr. Method of administration of PROMIS scales did not significantly impact score level, reliability, or validity. J Clin Epidemiol. 2014;67(1):108–13.
Meirte J, et al. Benefits and disadvantages of electronic patient-reported outcome measures: systematic review. JMIR Perioper Med. 2020;3(1):e15588.
Kluetz PG, et al. Focusing on Core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms (in eng). Clin Cancer Res. 2016;22(7):1553–8. https://doi.org/10.1158/1078-0432.Ccr-15-2035.
Rosenbloom S, et al. Development and validation of eleven symptom indexes to evaluate response to chemotherapy for advanced cancer: measurement compliance with regulatory demands. In: The value of innovation: impact on health, life quality, safety, and regulatory research; 2008. p. 53–66.
Cella D, et al. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Cancer Netw. 2011;9(3):268–78.
Rosenbloom S, et al. Development and validation of eleven symptom indexes to evaluate response to chemotherapy for advanced cancer: measurement compliance with regulatory demands. In: The value of innovation: impact on health, life quality, safety, and regulatory research. Bingley: Emerald Group Publishing Limited; 2007.
Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1(1):1–7.
Cella D, Webster K. Linking outcomes management to quality-of-life measurement. Oncology (Williston Park). 1997;11(11A):232–5.
Jensen SE, et al. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol. 2011;120(2):214–9.
Jensen SE, Beaumont JL, Jacobsen PB, Abernethy A, Syrjala KL, Cella D. Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index. J Support Oncol. 2013;11(2):86.
Hlubocky FJ, et al. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy–Lymphoma Symptom Index. Leuk Lymphoma. 2013;54(9):1942–6.
Garcia SF, et al. Priority symptoms in advanced breast cancer: development and initial validation of the National comprehensive cancer Network-Functional assessment of cancer Therapy-Breast cancer symptom index (NFBSI-16). Value Health. 2012;15(1):183–90.
Yount S, et al. A brief symptom index for advanced lung cancer. Clin Lung Cancer. 2012;13(1):14–23.
Victorson DE, Beaumont JL, Rosenbloom SK, Shevrin D, Cella D. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psycho-Oncology. 2011;20(9):977–83.
Colwell HH, et al. Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness. Oncologist. 2010;15(3):308.
Butt Z, et al. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). Cancer. 2012;118(23):5997–6004.
Rothrock NE, et al. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer. Value Health. 2013;16(5):789–96.
Oswald LB, Lee JW, Argiris A, Webster KA, Forastiere AA, Cella D. Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a trial of the ECOG-ACRIN Cancer Research Group (E1302). Cancer Med. 2020;9(23):8884–94.
Basch E, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
Pearman T, Yanez B, Peipert J, Wortman K, Beaumont J, Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer. 2014;120(18):2902–9.
Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28(2):192–211.
Butt Z, Peipert J, Webster K, Chen C, Cella D. General population norms for the functional assessment of cancer therapy–Kidney Symptom Index (FKSI). Cancer. 2013;119(2):429–37.
Holzner B, et al. Normative data for functional assessment of cancer therapy general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol. 2004;43(2):153–60.
Janda M, DiSipio T, Hurst C, Cella D, Newman B. The Queensland cancer risk study: general population norms for the Functional Assessment of Cancer Therapy–General (FACT-G). Psycho-Oncology. 2009;18(6):606–14.
Bagge A-SL, Carlander A, Fahlke C, Bagge RO. Health-related quality of life (FACT-GP) in general Swedish population. Eur J Surg Oncol. 2020;46(2):e7–8.
Montan I, Löwe B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)-Fatigue Scale. Value Health. 2018;21(11):1313–21.
Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–38.
Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz H-J, Nortier JW. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003;21(2):366–73.
Lange M, Heutte N, Morel N, Eustache F, Joly F, Giffard B. Cognitive complaints in cancer: the French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog), normative data from a healthy population. Neuropsychol Rehabil. 2016;26(3):392–409.
Lai J-S, et al. Parent-perceived child cognitive function: results from a sample drawn from the US general population. Childs Nerv Syst. 2011;27(2):285–93.
Munoz AR, Salsman JM, Stein KD, Cella D. Reference values of the functional assessment of chronic illness therapy-spiritual well-being: a report from the American Cancer Society’s studies of cancer survivors. Cancer. 2015;121(11):1838–44.
Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution-and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39(10):1039–47.
Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag. 2002;24(6):547–61.
Hay RR, D. Reliability and validity (including responsiveness). In: Hays PFR, editor. Assessing quality of life in clinical trials: methods and practice. 2nd ed. Oxford: Oxford University Press; 2005. p. 525–39.
Devji T, et al. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ. 2020;369:m1714.
Yost KJ, Eton DT. Combining distribution-and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28(2):172–91.
Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer. 2006;106(3):494–504.
Fayers PM, Hays RD. Don’t middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Qual Life Res. 2014;23(1):1–4.
Salsman JM, Beaumont JL, Wortman K, Yan Y, Friend J, Cella D. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Support Care Cancer. 2015;23(5):1355–64.
Rebelo P, Oliveira A, Andrade L, Valente C, Marques A. Minimal clinically important differences for patient-reported outcome measures of fatigue in patients with COPD following pulmonary rehabilitation. Chest. 2020;158(2):550–61.
Garland SN, et al. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer. 2011;117(6):1302–12.
Peipert JD, et al. Validation of the Functional Assessment of Cancer Therapy–Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. Cancer. 2020;126(15):3542–51.
King MT, Agar M, Currow DC, Hardy J, Fazekas B, McCaffrey N. Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). Support Care Cancer. 2020;28(1):141–53.
Yount S, et al. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007;16(10):1615–26.
Cella D, et al. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res. 2013;22(5):1105–12.
Cella D, et al. What is a clinically meaningful change on the functional assessment of cancer therapy–lung (FACT-L) questionnaire?: results from eastern cooperative oncology group (ECOG) study 5592. J Clin Epidemiol. 2002;55(3):285–95.
Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12(1):124–9.
Steel J, Eton DT, Cella D, Olek M, Carr B. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006;17(2):304–12.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference (in eng). Contr Clin Trials. 1989;10(4):407–15. https://doi.org/10.1016/0197-2456(89)90005-6.
Cheung YT, et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67(7):811–20.
Cheng HL, et al. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health Qual Life Outcomes. 2020;18(1):1–9.
Wong S-F, et al. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020;4(1):1–12.
U.S. Food and Drug Administration. Discussion document for patient-focused drug development public workshop on guidance 4: incorporating clinical outcome assessments into endpoints for regulatory decision-making. Silver Spring: United States Department of Health and Human Services; 2019.
U.S. Food and Drug Administration. Discussion document for patient-focused drug development public workshop on guidance 3: select, develop or modify fit-for-purpose clinical outcome assessments. Silver Spring: United States Department of Health and Human Services; 2018.
Jensen RE, et al. Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Qual Life Res. 2015;24(10):2333–44.
Jensen RE, et al. Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort. Cancer. 2017;123(2):327–35.
Coon CD, Cook KF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res. 2018;27(1):33–40.
Hays RD, Peipert JD. Minimally important differences do not identify responders to treatment. JOJ Sci (Juniper Publishers Inc.). 2018;1(1):4–5.
Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol. 1997;50(8):869–79.
McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):163–9.
Hays RD, Brodsky M, Johnston MF, Spritzer KL, Hui K-K. Evaluating the statistical significance of health-related quality-of-life change in individual patients. Eval Health Prof. 2005;28(2):160–71.
King MT, Dueck AC, Revicki DA. Can methods developed for interpreting group-level patient-reported outcome data be applied to individual patient management? Med Care. 2019;57(Suppl 5 1):S38.
Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–9. https://doi.org/10.1037/0022-006X.59.1.12.
Hays RD, Spritzer KL, Sherbourne CD, Ryan GW, Coulter ID. Group and individual-level change on health-related quality of life in chiropractic patients with chronic low back or neck pain. Spine. 2019;44(9):647.
Pearman TP, Beaumont JL, Mroczek D, O’Connor M, Cella D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer. 2018;124(5):991–7.
Peipert J, et al. Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients. American Society of Clinical Oncology; 2020.
Wagner LI, et al. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA. 27 (E1Z03). Breast Cancer Res Treat. 2018;169(3):537–48.
Yanez B, Pearman T, Lis C, Beaumont J, Cella D. The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol. 2013;24(4):1073–8.